Pharmaron shareholder completes planned equity reduction

Pharmaron Beijing (SZSE:300759) announced that Shenzhen Sino-Alliance Kangcheng Investment Partnership and its consistent acting person, Shenzhen Sino-Alliance Longcheng Investment Partnership, have completed their planned share reduction. Between January 22, 2025, and March 6, 2025, Sino-Alliance Kangcheng reduced its holdings by 9,066,716 shares through block trades at an average price of 26.36 CNY. Additionally, Sino-Alliance Kangcheng disposed of 1,600,000 shares via centralized bidding at an average price of 28.35 CNY, concluding on February 20, 2025. The total reduction amounted to 10,666,716 shares, representing 0.60% of Pharmaron's total share capital. Following these transactions, Sino-Alliance Kangcheng's stake decreased from 14.67% to 14.07%, while Sino-Alliance Longcheng remains at 1.60%. Pharmaron affirmed that this share reduction aligns with regulations and will not alter the company's control structure.